Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Netscientific Appoints Ian Postlethwaite as CFO

5 Apr 2016 07:00

RNS Number : 1367U
NetScientific PLC
05 April 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

 

London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

 

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

 

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

 

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

 

 

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

 

Allergy Therapeutics Italia s.r.l.

 

Allergy Therapeutics Iberia S.L.

 

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

 

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALFFEISRISIIR
Date   Source Headline
8th Jun 20214:36 pmRNSPrice Monitoring Extension
8th Jun 20211:40 pmRNSPDS Announces Release of PDS0101 Interim Data
8th Jun 202111:05 amRNSSecond Price Monitoring Extn
8th Jun 202111:00 amRNSPrice Monitoring Extension
7th Jun 20214:40 pmRNSSecond Price Monitoring Extn
7th Jun 20214:35 pmRNSPrice Monitoring Extension
7th Jun 20212:06 pmRNSSecond Price Monitoring Extn
7th Jun 20212:00 pmRNSPrice Monitoring Extension
7th Jun 20217:00 amRNSProAxsis Update
3rd Jun 20214:30 pmRNSResult of AGM
3rd Jun 20218:14 amRNSHolding(s) in Company
28th May 20212:20 pmRNSHolding(s) in Company
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
24th May 20217:00 amRNSProAxsis Update
21st May 202111:00 amRNSPrice Monitoring Extension
20th May 20214:19 pmRNSPDS Announces Release of PDS0101 Abstract
20th May 20217:00 amRNSEMV Capital Advises on £3.4m PointGrab Fundraise
18th May 20217:00 amRNSPDS receives $4.5m from net sale of tax benefits
13th May 20213:15 pmRNSPDS Reports Results for Q1 2021 & Business Update
13th May 20217:00 amRNSEMV Capital Advises on £2.9m SageTech Fundraise
30th Apr 20217:00 amRNSPDS Announces Presentation at ASCO Annual Meeting
28th Apr 202110:08 amRNSEMV Capital Advises on £740k Fundraise for Sofant
14th Apr 20212:25 pmRNSNotice of AGM and Annual Report & Accounts
31st Mar 20219:02 amRNSPreliminary Results for the year ended 31 Dec 2020
30th Mar 20217:00 amRNSNotice of Results & Investor Presentation
18th Mar 202111:48 amRNSPDS Reports Results for FY2020 & Business Update
11th Mar 20213:26 pmRNS$60m Commitment for PDS Vaccine Consortium
23rd Feb 20217:00 amRNSPDS Biotech Consortium Update
22nd Feb 20217:00 amRNSProAxsis Update
10th Feb 202111:01 amRNSPrice Monitoring Extension
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
5th Feb 20212:06 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 202111:05 amRNSSecond Price Monitoring Extn
5th Feb 202111:00 amRNSPrice Monitoring Extension
3rd Feb 20212:45 pmRNSPDS Phase II Trial Update & Restoration of Trading
3rd Feb 20212:45 pmRNSRestoration - Netscientific plc
2nd Feb 20217:30 amRNSSuspension - Netscientific plc
2nd Feb 20217:00 amRNSSuspension of Trading on AIM
25th Jan 20217:00 amRNSIssue of Shares, Director/PDMR Shareholding & TVR
4th Jan 202110:31 amRNSHolding(s) in Company
21st Dec 20202:59 pmRNSPDS Announces Publication of Data by Mount Sinai
10th Dec 20207:00 amRNSProAxsis awarded Innovate UK grant
7th Dec 202011:05 amRNSSecond Price Monitoring Extn
7th Dec 202011:00 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSBoard changes and Grant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.